Purification and characterization of an endogenous protein modulator of radioligand binding to “peripheral-type” benzodiazepine receptors and dihydropyridine ca2+-channel antagonist binding sites
References (40)
- et al.
Eur. J. Pharmac.
(1981) - et al.
Eur. J. Pharmac.
(1981) - et al.
Neurosci. Lett.
(1982) - et al.
Eur. J. Pharmac.
(1980) - et al.
Pharmac. Biochem. Behav.
(1984) - et al.
Life Sci.
(1984) - et al.
Eur. J. Pharmac.
(1985) - et al.
Eur. J. Pharmac.
(1985) - et al.
Eur. J. Pharmac.
(1986) - et al.
Life Sci.
(1984)
Life Sci.
(1985)
Fedn Eur. Biochem. Soc. Lett.
(1984)
Analyt. Biochem.
(1983)
J. biol. Chem.
(1951)
Life Sci.
(1983)
Life Sci.
(1985)
Brain Res.
(1984)
Science
(1977)
Nature, Lond.
(1977)
Cited by (22)
The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development
2006, Pharmacology and TherapeuticsDesign, synthesis and structure-affinity relationships of aryloxyanilide derivatives as novel peripheral benzodiazepine receptor ligands
2004, Bioorganic and Medicinal ChemistryCitation Excerpt :As endogenous ligands for peripheral benzodiazepine receptors (PBRs), anthraline, diazepam-binding inhibitor (DBI) and proptoporphyrin IV have been reported. Anthraline, 16 kDa protein, binds to both PBR and the dihydropyridine binding sites.26 DBI, a 104 amino acid neuropeptide,27 has been found in human brain, and DBI-like immunoreactivity has been found in the cerebrospinal fluid of human volunteers.28
Peripheral-type benzodiazepine receptors
1997, General PharmacologyPeripheral-type benzodiazepine receptors
1993, Life Sciences
- §
Present address: Merck Sharp & Dohme Research Laboratories, West Point, PA 19486.
Copyright © 1988 Published by Elsevier Inc.